True To Its Cancer Focus, Medarex Outlicenses C. Diff Therapy To Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
Medarex and partner Massachusetts Biologic Laboratories will split equally $60 million upfront and potential milestones worth $165 million.
You may also be interested in...
Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio
BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.
Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio
BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.
Generic Vancocin Gets Cmte. Endorsement, But So Do New Brand Products
When the Pharmaceutical Science and Clinical Pharmacology Advisory Committee endorsed dissolution data for establishing bioequivalence of generic versions of Vancocin, it not only paved the way for generic applicants, but it also highlighted the need for additional, more accommodating forms of the drug